The Mayo Clinic Cancer Center (MCCC) is poised to provide an exceptional career development experience for academic oncologists and translational cancer researchers who seek to establish a career in patient- oriented research. A National Cancer Institute (NCI)-designated comprehensive cancer center with 40+ years of continuous funding, the MCCC remains at the epicenter of high-quality, practice-changing research. Its funding portfolio includes an NCI-funded Phase I grant; a Phase II contract; 5 Specialized Programs of Research Excellence (SPORE's) in cancers of the brain, breast, ovary, pancreas as well as lymphomas (the latter is a 2-institution, shared SPORE); and multiple investigator-initiated grants. It maintains strong ties to the national cancer clinical trals networks, including the Alliance. It is home to an NCI Community Oncology Research Program (NCORP) grant and a Cancer Prevention Network (CPN) contract. Similarly, the Mayo Graduate School of Medicine is one of the largest training programs in the world. In this application, the MCCC seeks to renew the Paul Calabresi Program in Clinical and Translational Research at the Mayo Clinic, requesting 5 positions at any one time for a dual track, M.D. and Ph.D. career development program. The MCCC has been privileged to hold this award since 2001. To date, all 33 Calabresi scholars remain engaged in translational cancer research; all have applied for peer-reviewed research funding; 94% have secured such funding; 10 have acquired R01 or R01-equivalent funding as a principal investigator (5 this past grant cycle); some hold leadership positions in academic oncology; and all have published in cancer therapeutics, cumulatively amassing 1500+ publications during and after their scholar tenure. In this application, scholars must focus on 1 of 5 research tracks that align with MCCC Programs: Gastrointestinal Malignancies, Hematology, Neuro-Oncology, Novel Therapeutics, or Women's Cancers. Multidisciplinary mentoring teams will work with each scholar as he/she completes coursework, embarks upon hands-on patient-oriented research, and strives for career independence. Administrative infrastructure consists of a principal investigator who has been committed to this training program since its inception, an internal advisory committee comprised of accomplished leaders/mentors within the MCCC, and an external advisory committee selected for its interest and renowned expertise in training a diverse academic work force in cancer research. The MCCC seeks to train another generation of investigators who will conduct cutting edge, hypothesis-driven, practice-changing research in cancer therapeutics.

Public Health Relevance

The Mayo Clinic Cancer Center (MCCC) seeks to renew the 'Paul Calabresi Program in Clinical and Translational Research at the Mayo Clinic,' requesting 5 positions at any one time for a dual track, M.D. and Ph.D. career development program. Since 2001, the MCCC has trained 33 successful Calabresi scholars and seeks to train another generation of investigators who will conduct cutting edge, hypothesis-driven, practice- changing research in cancer therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
2K12CA090628-16
Application #
9085585
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Damico, Mark W
Project Start
2001-09-25
Project End
2021-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
16
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Hampel, Paul J; Larson, Melissa C; Kabat, Brian et al. (2018) Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. Br J Haematol 183:421-427
Glumac, Paige M; Forster, Colleen L; Zhou, Hong et al. (2018) The identification of a novel antibody for CD133 using human antibody phage display. Prostate 78:981-991
Yan, Yiyi; Kumar, Anagha Bangalore; Finnes, Heidi et al. (2018) Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Front Immunol 9:1739
Miao, Diana; Margolis, Claire A; Gao, Wenhua et al. (2018) Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359:801-806
Mansfield, Aaron S; Peikert, Tobias; Vogelzang, Nicholas J et al. (2018) Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. Mayo Clin Proc 93:1026-1033
Haddad, Tufia C; D'Assoro, Antonino; Suman, Vera et al. (2018) Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. Breast Cancer Res Treat 168:639-647
Painuly, Utkarsh; Ramakrishnan, Vijay; Kimlinger, Teresa et al. (2018) Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. Oncotarget 9:34582-34594
Kim, Minjee; Ma, Daniel J; Calligaris, David et al. (2018) Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Mol Cancer Ther 17:1893-1901
Paludo, Jonas; Fritchie, Karen; Haddox, Candace L et al. (2018) Extraskeletal Osteosarcoma: Outcomes and the Role of Chemotherapy. Am J Clin Oncol 41:832-837
Durani, Urshila; Gallo de Moraes, Alice; Beachey, Joel et al. (2018) Epithelioid angiosarcoma: A rare cause of pericarditis and pleural effusion. Respir Med Case Rep 24:77-80

Showing the most recent 10 out of 243 publications